Benitec Biopharma (BNTC) announced the recommendation of the independent Data Safety Monitoring Board to continue enrollment of the Phase 1b/2a Clinical Treatment Study following completion of the comprehensive review of safety information for all six Subjects enrolled into Cohort 1. Following the positive DSMB recommendation, enrollment of Cohort 2 is expected to begin in Q4 2025. In accordance with the Protocol for the BB-301 Phase 1b/2a Clinical Treatment Study, a meeting of the DSMB was convened following the completion of the 28-day post BB-301 dosing visit for the sixth Subject enrolled into Cohort 1. The DSMB recommended the continuation of Subject enrollment for the Phase 1b/2a Clinical Treatment Study. Following the positive DSMB recommendation, enrollment of Cohort 2 is expected to begin in Q4 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTC:
- Benitec Biopharma initiated with a Buy at TD Cowen
- Innovative Gene Therapy Approach Drives Buy Rating for Benitec Biopharma
- Benitec Biopharma files to sell 900K shares of common stock for holders
- Positive Buy Recommendation for Benitec Biopharma Driven by Promising Clinical Progress and Strong Financial Position
- Benitec Biopharma reports Q3 EPS (24c) vs. (23c) last year